Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 37/2026 September 13, 2026
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026
Phase 1 Results for 225Ac-LNC1011, a Novel Alpha Emitter Therapy for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxDiWB-1: A Targeted Approach to Prostate Cancer Treatment
/in Pepetide-Drug Conjugate, Preclinical Research/by MaxDiWB-1, a luteinizing hormone-releasing hormone (LHRH)-targeted peptide-drug conjugate (PDC) with PI3K inhibition properties, is an emerging candidate that may offer a new way to treat prostate cancer. Its design and mechanism suggest potential for addressing some of the limitations of current treatments, particularly for resistant cases. DiWB-1 is described as an LHRH-targeted PDC, a class […]
New Method Uses Nanoparticles to Create CAR T Cells Inside Body for Cancer Treatment
/in mRNA, Preclinical Research/by MaxPhase 1 Trial for ART-101, a Novel Radioligand Targeting PSMA in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 For a New PARP1 Inhibitor: EIK1004 (IMP1707) For mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Trial: MT-4561 Targeting BRD4 in Metastatic Prostate Cancer and Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxNEPC
Real-World Studies Suggest Survival Advantage with Apalutamide in mCSPC Treatment
/in Retrospective studies/by MaxPhase 2 Trial: ZG006 a New Immunotherapy for Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by Max